NCE-1 Intelligence & Market Opportunity

Vonjo

Pacritinib

Anticancer

Oral Capsule

Approval Date

28-Feb-22

NCE-1 Date

28-Feb-26

NCE Date

28-Feb-27

Commercial snapshot

Market performance & projections

Revenue ($M)

127

CAGR (%)

0.1188

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

131

2027

150

2028

179

2029

199

2030

221

2031

241

2032

245

Molecule profile

Details & specifications

Molecule

Pacritinib

Innovator

SOBI, INC.

Dosage Form

Oral Capsule

Strength

EQ 100 mg base

Therapeutic Category

Anticancer

Usage

To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.